Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates.
A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals.
The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM).
According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases.
While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: and .
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
20 minutes ago
- USA Today
Nasdaq tops NYSE in 2025 IPO race with $21.3 billion in listings
Nasdaq handily beat the New York Stock Exchange in stock market listings during the first half of 2025, buoyed by blockbuster initial public offerings of big names like CoreWeave CRWV.O and Chime CHYM.O and a jump in proceeds raised via special purpose acquisition companies. IPOs at Nasdaq NDAQ.O, including those of blank-check acquisition companies, raised about $21.3 billion during the first half, compared with $8.7 billion for flotations at the NYSE ICE.N, according to data from Dealogic. Excluding SPAC volumes, traditional IPOs on the Nasdaq raised roughly $9 billion from 79 deals, while 15 IPOs on NYSE raised about $7.8 billion. Last year during the same period, Nasdaq IPOs had raised about $6.1 billion, while shares worth $11.5 billion were sold from IPOs on NYSE. Stock market launches dropped off sharply during the April market selloff that was driven by erratic U.S. trade policy, but Wall Street has since recovered and companies are starting to rush back to seek listings. "We felt this year had an opportunity to be good - and then we had enormous volatility to start the year, so companies across the board had to go pencils down," Nasdaq President Nelson Griggs told Reuters. "Clearly now, with the market rebound we've had after a very strong May, companies are back having those discussions. If the next round (of companies) does well, I think you're going to really see some excitement for the fall," Griggs added. More financial markets: Stocks usually rise by 10% a year. Those days may be over. The Nasdaq Composite .IXIC and S&P 500 .SPX reached record closing highs on Monday, capping their best quarter in more than a year. With its first-half listings performance, Nasdaq maintained its stranglehold at the top of the rankings. The exchange operator has led the IPO rankings ahead of NYSE during the better part of the past decade, including the last six years, according to Dealogic. The market share battle between the two top U.S. exchanges and the improving outlook for stock market listings follows an arid spell for capital markets that lasted for more than two years. Several big names, including medical supply giant Medline and design software maker Figma are gearing up for IPOs later this year. Liquefied natural gas exporter Venture Global's VG.N $1.75 billion share sale, CoreWeave's $1.5 billion raise, and cybersecurity firm SailPoint's SAIL.O $1.38 billion offering ranked as the biggest U.S. IPOs during the first half. "The largest IPO YTD is listed on the NYSE. We anticipate that issuance for the remainder of the year will continue to be active," NYSE Global Head of Capital Markets Michael Harris said. High-profile switches Both exchanges have been beneficiaries of large corporations transferring listings from one venue to the other. This year, Nasdaq has received a boost from high-profile switches including those of Kleenex tissue maker Kimberly-Clark KMB.O and content and technology company Thomson Reuters the parent company of Reuters News. Nasdaq said 10 companies with a combined market value of $271.4 billion have switched from the NYSE this year, the best first-half performance for the exchange operator since it started tracking the data from 2006. NYSE was buoyed by transfers from five companies including financial services firm Virtu VIRT.N, CSW Industrials CSW.N, and building products distributor QXO QXO.N in the first half. Some companies that transferred from NYSE to Nasdaq this year cited the attractiveness of the Nasdaq-100 index .NDX - which includes 100 of the most valuable non-financial companies listed on the Nasdaq, including the likes of Nvidia NVDA.O and Apple AAPL.O - as being a key driver for the decision to switch. The Nasdaq 100 has risen nearly 8% this year, compared to the S&P 500 .SPX, which has climbed about 5.5% year-to-date. "We realized very quickly that Nasdaq had something that was very compelling - if you are in the Nasdaq and you meet the threshold for the market cap, you can be part of the Nasdaq-100, a great index to be a member of," said Juan Pelaez, vice-president of investor relations at chemicals company Linde LIN.O, which switched to Nasdaq in 2023. The rivalry between Nasdaq and NYSE has played a big role in making U.S. capital markets more attractive for investors, compared to other markets like Hong Kong and London, which currently have only one venue for flotations, according to experts. Reporting by Anirban Sen in New York; Editing by Alden Bentley and Jamie Freed
Business Wire
25 minutes ago
- Business Wire
Asbury Automotive Group Schedules Release of Second Quarter 2025 Financial Results
DULUTH, Ga.--(BUSINESS WIRE)--Asbury Automotive Group, Inc. (NYSE: ABG), one of the largest automotive retail and service companies in the U.S., announced that it will release its second quarter financial results before the market opens on Tuesday, July 29, 2025. Asbury will host a conference call later that day at 10:00 a.m. Eastern Time. The conference call will be simulcast live on the internet and can be accessed by logging onto A replay will be available on this site for 30 days. In addition, live audio will be accessible to the public. Participants may enter the conference call five to ten minutes prior to the scheduled start of the call by dialing: About Asbury Automotive Group, Inc Asbury Automotive Group, Inc. (NYSE: ABG), a Fortune 500 company headquartered in Duluth, GA, is one of the largest automotive retailers in the U.S. In late 2020, Asbury embarked on a multi-year plan to increase revenue and profitability strategically through organic operations, acquisitive growth and innovative technologies, with its guest-centric approach as Asbury's constant North Star. As of June 30, 2025, Asbury operated 145 new vehicle dealerships, consisting of 189 franchises and representing 31 domestic and foreign brands of vehicles. Asbury also operates Total Care Auto, Powered by Landcar, a leading provider of service contracts and other vehicle protection products, and 37 collision repair centers. Asbury offers an extensive range of automotive products and services, including new and used vehicles; parts and service, which includes vehicle repair and maintenance services, replacement parts and collision repair services; and finance and insurance products, including arranging vehicle financing through third parties and aftermarket products, such as extended service contracts, guaranteed asset protection debt cancellation, and prepaid maintenance. Asbury is recognized as one of America's Fastest Growing Companies 2024 by the Financial Times and the Company is listed in World's Most Trustworthy Companies 2024 by Newsweek. For additional information, visit
Yahoo
38 minutes ago
- Yahoo
Nasdaq, S&P 500 Retreat After Record Highs as Traders Parse Powell's Comments
The Nasdaq Composite and the S&P 500 fell from record levels as investors weighed Federal Reserve Ch Sign in to access your portfolio
